Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss ⊖
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.